A Phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 42-49

  Britten, Carolyn D ^a,e   Rowinsky, Eric K ^a   Baker, Sharyn D ^a   Weiss, Geoffrey R ^a   Smith, Lon ^a   Stephenson, Joseph ^c   Rothenberg, Mace ^a   Smetzer, Leslie ^b   Cramer, Jeffrey ^d   Collins, William ^d   Von Hoff, Daniel D ^a   Eckhardt, S Gail ^a  

^a CTRC Institute for Drug Development   (United States)

^b TEXAS ONCOLOGY   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOMAGNESEMIA; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MAGNESIUM; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MITOCHONDRIA; NEOPLASMS; PROTEINURIA; PYRIDINES; THIAZOLES; TISSUE DISTRIBUTION;

EID: 0033956563     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Koya, K., Li, L., Wang, H., Ukai, T., Tatsuta, N., Kawakami, M., Shishido, T., and Chen, L. B. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res., 56: 538-543, 1996.
2. MKT-077 Investigator's Brochure. Sandoz Research Institute, 1996.
3. Kawakami, M., Koya, K., Ukai, T., Tatsuta, N., Ikegawa, A., Ogawa, K., Shishido, T., and Chen, L. B. Structure-activity of novel rhodacyanine dyes as antitumor agents. J. Med. Chem., 41: 130-142, 1998.
4. Johnson, L. V., Walsh, M. L., and Chen, L. B. Localization of mitochondria in living cells with rhodamine 123. Proc. Natl. Acad. Sci. USA, 77: 990-994, 1980.
5. Johnson, L. V., Walsh, M. L., Bockus, B. J., and Chen, L. B. Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy. J. Cell Biol., 88: 526-535, 1981.
6. Davis S., Weiss, M. J., Wong, J. R., Lampidis, T. J., and Chen, L. B. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J. Biol. Chem., 260: 13844-13850, 1985.
7. Modica-Napolitano, J. S., and Aprille, J. R. Basis for the selective cytotoxicity of rhodamine 123. Cancer Res., 47: 4361-4365, 1987.
8. Nadakavukaren, K. K., Nadakavukaren, J. J., and Chen, L. B. Increased rhodamine 123 uptake by carcinoma cells. Cancer Res., 45: 6093-6099, 1985.
9. Emaus, R. K., Grunwald, R., and Lemasters, J. J. Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. Biochim. Biophys. Acta, 850: 436-448, 1986.
10. Summerhayes, I. C., Lampidis, T. J., Bemal, S. D., Nadakavudaren, J. J., Nadakavukaren, K. K., Shepherd, E. L., and Chen, L. B. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc. Natl. Acad. Sci. USA, 79: 5292-5296, 1982.
11. Modica-Napolitano, J. S., Koya, K., Weisberg, E., Brunelli, B. T., Li, Y., and Chen. L. B. Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077. Cancer Res., 56: 544-550, 1996.
12. Modica-Napolitano, J. S., Brunelli, B. T., Koya, K., and Chen, L. B. Photoactivation enhances the mitochondrial toxicity of the cationic rhodacyanine MKT-077. Cancer Res., 58: 71-75, 1998.
13. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science (Washington DC), 281: 1309-1312, 1998.
14. Kroemer, G., Dallaporta, B., and Resche-Rigon, M. The mitochondrial death/life regulator in apoptosis and necrosis. Ann. Rev. Physiol., 60: 619-642, 1998.
15. Mignotte, B., and Vayssiere, J. L. Mitochondria and apoptosis. Eur. J. Biochem., 252: 1-15, 1998.
16. Shankar-Narayan, K., Carl, J., Arcadi, J. A., and Jones, L. W. Comparative cytotoxicity of rhodamine 123 and MKT-077 on prostate cancer and non-tumorigenic cells in vitro. Proc. Am. Assoc. Cancer Res., 38: 220, 1997.
17. Chiba, Y., Kubota, T., Watanabe, M., Otani, Y., Teramoto, T., Matsumoto, Y., Koya, K., and Kitajima, M. Selective antitumor activity of MKT-077, a delocalized lipophilic cation, on normal cells and cancer cells in vitro. J. Surg. Oncol., 69: 105-110, 1998.
18. Petit, T., Izbicka, E., Lawrence, R. A., Nalin, C., Weitman, S. D., and Von Hoff, D. D. Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units. Anticancer Drugs, 10: 309-315, 1999.
19. Chiba, Y., Kubota, T., Watanabe, M., Matsuzaki, S. W., Otani, Y., Teramoto, T., Matsumoto, Y., Koya, K., and Kitajima, M. MKT-077, localized lipophilic cation: Antitumor activity against human tumor xenografts serially transplanted into nude mice. Anticancer Res., 18: 1047-1052, 1998.
20. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
21. Gibaldi, M., and Perrier, D. Pharmacokinetics, 2nd ed., pp. 409-417. New York, NY: Marcel Dekker, 1982.
22. Modica-Napolitano, J. S., Weiss, M. J., Chen, L. B., and Aprille, J. R. Rhodamine 123 inhibits bioenergetic function in isolated rat liver mitochondria. Biochem. Biophys. Res. Commun., 118: 717-723, 1984.
23. Mai, M. S., and Allison, W. S. Inhibition of an oligomycin-sensitive ATPase by cationic dyes, some of which are atypical uncouplers of intact mitochondria. Arch. Biochem. Biophys., 221: 467-476, 1983.
24. Kelepouris, E., and Agus, Z. S. Hypomagnesemia. Renal magnesium handling. Semin. Nephrol., 18: 58-73, 1998.
25. Sadoff, L. Nephrotoxicity of streptozotocin (NSC-85998). Cancer Chemother. Rep., 55: 303-307, 1971.
26. Tatsuta, N., Suzuki, N., Mochizuki, T., Koya, K., Kawakami, M., Shishido, T., Motoji, N., Kuroiwa, M., Shigematsu, A., and Chen, L. B. Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent. Cancer Chemother. Pharmacol., 43: 295-301, 1999.
27. Weisberg, E. L., Koya, K., Modica-Napolitano, J., Li, Y., and Chen, L. B. In vivo administration of MKT-077 causes partial yet reversible impairment of mitochondrial function. Cancer Res., 56: 551-555, 1996.
28. Lampidis, T. J., Salet, C., Moreno, G., and Chen, L. B. Effects of the mitochondrial probe rhodamine. 123 and related analogs on the function and viability of pulsating rnyocardial cells in culture. Agents Actions, 14: 751-757, 1984.
29. Rodriguez, G. I., Kuhn, J. G., Weiss, G., De La Cruz, P., New, P., Fields, S. M., Eckardt, J. R., Campbell, L., Clark, G. M., Hilsenbeck, S. G., and Von Hoff, D. D. A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Invest. New Drugs, 16: 57-67, 1998.